Yohei Doi

Get ready for #IDWeek2025 with our first IDWeek Daily News preview issue! Event highlights, session previews, daily schedules and much more. Read all about it: pageturnpro.com/JHCLLC/112745-…

@kcmolinaID @MattMil81732351 Congratulations! This was a big lift for a brand new chapter. I truly appreciate your hard work.

Proud to see our Mandells PPID chapter on the antibiotic pipeline published. A huge career bucket list item for me since I started in ID. Special thanks to my collaborators: our editor @yohei_doi and co-authors @MattMil81732351 and Gerry Barber.

Join us this March 2025 in Tokyo for the 60th Anniversary of the U.S.-Japan Cooperative Medical Sciences Program (USJCMSP)/Conference on Emerging Infectious Diseases. Confirmed speakers include Nobel Laureates, and NIAID Director Dr. Marazzo @DrJeanneM. lnkd.in/gfh9brrt

A seven-day course of antibiotics for hospitalized patients with bloodstream infections is just as effective as a 14-day course, according to new findings presented at #IDWeek2024. Learn more: idsociety.org/news--publicat…

We're thrilled to announce Bernard (Beej) Macatangay, MD, as the new Chief of our division! We also extend our gratitude to John Mellors, MD, for his 25 years of service as Division Chief. Thank you, Dr. Mellors, and congratulations Dr. Macatangay! #idpittstop

@padstamundo Thanks Patrick, we're working on it!

Cephamycins for ESBLs might be a useful option; observational study of cefmetazole vs meropenem for invasive UTI caused by ESBL E coli. Needs an RCT - luckily there is one in progress .. In Japan (center6.umin.ac.jp/cgi-open-bin/c…) journals.asm.org/doi/abs/10.112…

We (@Tokotoko1807 et al) experienced human coronavirus OC43 outbreak at a LTCF. We highlighted the importance of recognition that non-#SARSCoV2 respiratory viral infections may cause institutional #outbreaks doi.org/10.1017/ash.20…

New from @Tokotoko1807, @yohei_doi Authors found discontinuing universal preadmission screening for SARS-CoV-2 did not increase the trend in nosocomial clusters during community-based surges, supporting safety of the practice change. 📄: doi.org/10.1017/ice.20…

If you are attending @ESCMID in Copenhagen, don't forget to visit the @IDWeek2023 booth B3-03 at #ECCMID2023 to learn more about #IDWeek2023 in Boston! You've got questions, we've got answers!✅ Come by and see us today. 😀

@JorgeEVidal1 Fascinating story on heme toxicity and pneumococcal disease by @JorgeEVidal1 #ARIPanelEID

Dr. @yohei_doi and myself are co-chairing the Acute Respiratory Infections (ARI) panel tomorrow within the EID mtg in the pacific rim. Thanks to Dr. Xin-Xing Gu PO at NIAID-NIH for the invitation. In the pic also one of our speakers Dr. Yen from Hong Kong University #ARIpanelEID

@OncIDPharmd @PaulSaxMD Good question - it's approved since 2009 here but only for bacterial pneumonia, OM and sinusitis in children where other agents are deemed ineffective. Its sales never picked up, and CRE is still relatively uncommon.

Going to be very interesting to see what happens with this drug and carbapenem resistance. Anyone know what the effect has been in Japan, where the drug is already approved?

@EB_Hirsch @UMN_Pharmacy I was born there!

My shout out goes to Dr. Masaya Hibino, the first author who did most of the numerous interviews! (end)

Local surveillance and communication will be important in maintaining and boosting confidence in the vaccine as it is deployed in various populations. (11/n)

Our observation on the incidence of delayed injection site reaction from mRNA-1273 (aka Moderna arm) is now out in OFID! doi.org/10.1093/ofid/o… (1/n)